Table 4 Multivariable linear regression evaluating association between MAP values while receiving vasopressors and trial initiation
| Trial initiation defined by a dichotomous variable (pre-trial vs. during-trial periods) | Trial initiation defined by a three-category variable (pre-trial period, non-enrolled group, usual care control group) | ||||||
|---|---|---|---|---|---|---|---|
| Variable | β coefficient | 95% Confidence interval | p-value | Variable | β coefficient | 95% Confidence interval | p-value |
|
During-trial period (Non-enrolled + Usual care control groups) | 0.47 | (− 0.85, 1.80) | 0.48 | Non-enrolled group | 0.66 | (− 0.68, 2.00) | 0.33 |
| Usual care control group | 2.35 | (−0.11, 4.82) | 0.06 | ||||
| Pre-trial period | Reference | Pre-trial period | Reference | ||||
| APACHE II, per 10-point increase | −0.07 | (−0.13, − 0.01) | 0.03 | APACHE II, per 10-point increase | − 0.06 | (− 0.12, − 0.001) | 0.04 |
| Chronic hypertension (yes) | −0.71 | (−1.72, 0.31) | 0.17 | Chronic hypertension (yes) | −0.71 | (−1.72, 0.31) | 0.17 |
| Age, per 5-year increase | −0.03 | (−0.1, 0.03) | 0.32 | Age, per 5-year increase | −0.05 | (−0.12, 0.02) | 0.18 |
| Site 1 | −1.22 | (−2.61, 0.16) | 0.08 | Site 1 | −1.11 | (−2.49, 0.27) | 0.11 |
| Site 2 | −1.32 | (−2.96, 0.31) | 0.11 | Site 2 | −1.32 | (−2.94, 0.30) | 0.11 |
| Site 3 | 1.01 | (−0.66, 2.68) | 0.24 | Site 3 | 1.17 | (−0.49, 2.83) | 0.17 |
| Site 5 | 5.63 | (2.05, 9.22) | 0.002 | Site 4 | Reference | ||
| Site 4 | Reference | ||||||
| Time from trial initiation to hospital admission | −0.001 | (−0.005, 0.002) | 0.39 | Time from trial initiation to hospital admission | −0.004 | (−0.009, 0.0004) | 0.07 |